Drug intelligence / Profile preview

GCA2021

Development stage: Preclinical
Lead developer: Guangzhou Green Cross Pharmaceutical
Modality: Small Molecules

Overview

GCA2021 (also referred to as GCF2023) is an innovative small molecule compound and new formulation being developed by Guangzhou Green Cross Pharmaceutical for the treatment of inflammatory conditions. According to the company's pipeline, the drug is currently in the CMC (Chemistry, Manufacturing, and Controls) stage, which involves the optimization of the manufacturing process and quality control standards prior to clinical testing. The dual code names suggest that GCA2021 represents the new chemical entity (NCE), while GCF2023 refers to the specific innovative formulation of that compound. It is part of the developer's portfolio of self-developed innovative drugs focused on rheumatology and immunology.

Beyond the preview

Go deeper on GCA2021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCA2021.

Explore the full profile